
In August, a marketing authorization application for the obesity drug Wegovy was sent off to the Japanese authorities (PMDA), Novo Nordisk reveals in its quarterly report for the third quarter.
Wegovy, which is built on the GLP-1 analog semaglutide, has been out in the US since June of this year, while a decision from the European Medicines Agency (EMA) is expected around the New Year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app